Pharmacological treatment of Parkinson's disease.
Münchau
A
A
National Hospital for Neurology and Neurosurgery, London WC1N 3BG, UK.
Bhatia
K P
KP
D000367:Age Factors; D000368:Aged; D000547:Amantadine / Q000627:therapeutic use; D000978:Antiparkinson Agents / Q000145:classification / Q000627:therapeutic use*; D001058:Apomorphine / Q000627:therapeutic use; D002394:Catechol O-Methyltransferase / Q000627:therapeutic use; D003937:Diagnosis, Differential; D018491:Dopamine Agonists / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008875:Middle Aged; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology
D000978:Antiparkinson Agents; D018491:Dopamine Agonists; D008996:Monoamine Oxidase Inhibitors; D007980:Levodopa; D000547:Amantadine; D002394:Catechol O-Methyltransferase; D001058:Apomorphine